Moleculin Biotech, Inc.

NasdaqCM:MBRX Stock Report

Market Cap: US$14.1m

Moleculin Biotech Management

Management criteria checks 3/4

We currently do not have sufficient information about the CEO.

Key information

Wally Klemp

Chief executive officer

US$1.3m

Total compensation

CEO salary percentage41.98%
CEO tenure11yrs
CEO ownership0.6%
Management average tenure9.4yrs
Board average tenure4.3yrs

Recent management updates

Recent updates

Analysis Article • Dec 20

We're A Little Worried About Moleculin Biotech's (NASDAQ:MBRX) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Analysis Article • Jul 14

Can Moleculin Biotech (NASDAQ:MBRX) Afford To Invest In Growth?

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analysis Article • Feb 18

Is Moleculin Biotech (NASDAQ:MBRX) In A Good Position To Deliver On Growth Plans?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Analysis Article • Nov 01

Here's Why We're Watching Moleculin Biotech's (NASDAQ:MBRX) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

CEO Compensation Analysis

How has Wally Klemp's remuneration changed compared to Moleculin Biotech's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2026n/an/a

-US$42m

Dec 31 2025US$1mUS$565k

-US$34m

Sep 30 2025n/an/a

-US$55m

Jun 30 2025n/an/a

-US$37m

Mar 31 2025n/an/a

-US$27m

Dec 31 2024US$1mUS$565k

-US$26m

Sep 30 2024n/an/a

-US$30m

Jun 30 2024n/an/a

-US$28m

Mar 31 2024n/an/a

-US$27m

Dec 31 2023US$1mUS$565k

-US$30m

Sep 30 2023n/an/a

-US$26m

Jun 30 2023n/an/a

-US$29m

Mar 31 2023n/an/a

-US$30m

Dec 31 2022US$2mUS$565k

-US$29m

Sep 30 2022n/an/a

-US$25m

Jun 30 2022n/an/a

-US$21m

Mar 31 2022n/an/a

-US$18m

Dec 31 2021US$2mUS$538k

-US$16m

Sep 30 2021n/an/a

-US$16m

Jun 30 2021n/an/a

-US$15m

Mar 31 2021n/an/a

-US$21m

Dec 31 2020US$2mUS$500k

-US$17m

Sep 30 2020n/an/a

-US$19m

Jun 30 2020n/an/a

-US$19m

Mar 31 2020n/an/a

-US$10m

Dec 31 2019US$2mUS$625k

-US$13m

Compensation vs Market: Wally's total compensation ($USD1.35M) is above average for companies of similar size in the US market ($USD659.85K).

Compensation vs Earnings: Wally's compensation has been consistent with company performance over the past year.

CEO

Wally Klemp (66 yo)

11yrs
Tenure
US$1,345,958
Compensation

Mr. Walter V. Klemp, also known as Wally, served as Executive Chairman of Autonomix Medical, Inc. since joining in January 2022 until December 2024. He Co-Founded Moleculin Biotech, Inc. in July 2015 and h...

Leadership Team

NamePositionTenureCompensationOwnership
Walter Klemp
Co-Founder11yrsUS$1.35m0.59%
$ 82.5k
Jonathan Foster
Executive VP & CFO9.9yrsUS$907.27k0.23%
$ 32.0k
Donald Picker
Chief Scientific Officer8.9yrsUS$622.92k0.013%
$ 1.8k
Waldemar Priebe
Co-Founderno datano datano data
John Waymack
Senior Chief Medical Officer4.8yrsno datano data
9.4yrs
Average Tenure
70yo
Average Age

Experienced Management: MBRX's management team is seasoned and experienced (9.4 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Walter Klemp
Co-Founder11yrsUS$1.35m0.59%
$ 82.5k
Waldemar Priebe
Co-Founderno datano datano data
Michael Cannon
Independent Director10.1yrsUS$120.22k0%
$ 0
Jorge Cortes
Member of Scientific Advisory Board1.7yrsno datano data
Daniel Von Hoff
Member of Scientific Advisory Board1.7yrsno datano data
Michael Andreeff
Member of Scientific Advisory Board1.7yrsno datano data
John Climaco
Lead Independent Director9yrsUS$135.22k0%
$ 0
Elizabeth Cermak
Independent Director5.8yrsUS$115.22k0%
$ 0
Martin Tallman
Member of Annamycin Scientific Advisory Board2.3yrsno datano data
Robert George
Independent Director10.1yrsUS$126.72k0.00075%
$ 105.7
Joy Yan
Independent Director4.3yrsUS$98.72k0%
$ 0
Giovanni Martinelli
Member of Scientific Advisory Board1.7yrsno datano data
4.3yrs
Average Tenure
68yo
Average Age

Experienced Board: MBRX's board of directors are considered experienced (4.3 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/05 11:30
End of Day Share Price 2026/07/02 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Moleculin Biotech, Inc. is covered by 6 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Sara NikH.C. Wainwright & Co.
Jason McCarthyMaxim Group
Kevin DeGeeterOppenheimer & Co. Inc.